An RNAi-based approach to blocking the production of complement pathway factors offers the potential to inhibit the uncontrolled complement activation that leads to many diseases. The agreement provides
In the pharmaceutical industry, clinical-trial data is of paramount importance for drug development, and must be backed up and protected against any potential mishaps. Therefore, a Hybrid Cloud
The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic
Cerevel Therapeutics has secured $350m funding from funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences. They have also committed to provide further capital if
RPD designation for progeria and progeroid laminopathies enables priority review voucher (PRV) eligibility upon FDA approval of a rare pediatric disease product application for lonafarnib for these ultra-rare
The GEOMETRY mono-1 study showed an overall response rate (ORR) of 72.0% (95% CI: 50.6-87.9) in treatment-naive patients and 39.1% (95% CI: 27.6-51.6) in previously treated patients. ORR
New investors HBM Healthcare Investments (Cayman) and Nextech Invest also took part in the mezzanine financing, said TP Therapeutics. The new capital secured by the clinical-stage precision oncology
For patients with metastatic EGFR-mutated NSCLC, targeted EGFR TKI therapies such as gefitinib, erlotinib, afatinib or osimertinib represent the first-line treatment of choice. However, patients eventually develop resistance
Earlier this month, the company said that Chronocort could not confirm its superiority over conventional treatment in endocrine control over a 24-hour period, which was the primary objective
Lynparza has been designed to exploit DNA damage response (DDR) pathway deficiencies, like the BRCA mutations, to preferentially eliminate cancer cells. Especially, in vitro studies have demonstrated that
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.